I have stated on here many times before, a buyout is not the "best case scenario" for long term THLD shareholders. Though we as shareholders basically have little to no say in the matter, a buyout within the next 12 months will not allow us to be rewarded in the sense of realizing the true long term potential of this company. I agree with daay that bids to acquire THLD following release of positive O/S data from the 404 trial could be in the $30 to $60 range. Compare that to a market cap value of Threshold as we progress over the next 12 to 24 months with respect to NDA filing for TH-302 soon after release of O/S data (404 trial), EMA and FDA approval for soft tissue sarcoma (406 trial), positive trial results in our on-going trials for indications in Advanced Leukemias (407 trial currently in phase 1), positive results from phase 1/2 trials in solid tumors (401 and 402 trials), in addition to other indications such as Multiple Myeloma and Prostate. Putting a potential valuation on Threshold Pharma is a difficult one, but 15 to 20 times the per share price of today is not far fetched.